Italian specialty pharma maker of branded drugs for rare diseases and primary-care therapeutic areas.
Italian specialty pharma maker of branded drugs for rare diseases and primary-care therapeutic areas.
Sells prescription drugs through its own sales forces in Europe and other regions, with rare-disease drugs priced high for small patient groups and older primary-care brands providing a steady base. Growth has relied partly on buying drug rights and companies, rather than only on in-house research.
In one line: A smaller, Italian Jazz Pharmaceuticals.
Moat: narrow (IP / patents, regulatory licence, distribution). Orphan-drug exclusivity and a long-standing branded sales network across Europe/Turkey.
Headquarters: Milan, Italy · Founded: 1926 · Employees: 4,693
Size Recordati (REC.MI) is an Italy Health Care company (Pharmaceuticals: Major) with a market value of $12.0B, the 23rd largest of 121 Italy companies the cockpit tracks. Shares closed at €52.80 on 18 Nov 2026.
Performance Over six months the shares gained 2.9%, against +8.3% for the median peer and +3.1% for the Italy market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 8.3% over the last twelve months (peer median +14.6%); the operating margin is 30.2% (peer median 20.6%).
Valuation It trades at 16.6× forward earnings against a peer median of 31.9× (3rd cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.0 points above its cost of capital (6.9% WACC).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €2.77B | €2.62B | €2.34B | €2.08B | €1.85B |
| Revenue growth | — | +12% | +12% | +12% | — |
| Gross profit | €1.97B | €1.79B | €1.60B | €1.42B | €1.29B |
| EBITDA | €1.05B | €926M | €827M | €708M | €620M |
| Net income | €524M | €444M | €417M | €389M | €312M |
| Free cash flow | €620M | €557M | €533M | €456M | €438M |
| Capital expenditure | €148M | €85.1M | €851M | €383M | €96.3M |
| Total debt | €2.20B | €2.47B | €2.48B | €1.81B | €1.72B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Recordati REC.MI | $12.0B | +3% | +8% | 30% | 16.6× | 1.1% |
| Jazz Pharmaceuticals Public JAZZ | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% |
| Ipsen IPN.PA | $14.8B | +1% | +14% | 30% | 10.8× | -6.7% |
| Swedish Orphan Biovitrum SOBI.ST | $16.1B | +6% | +15% | 30% | 24.1× | -2.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | REC.MI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.4% | +6.7% | 5th lowest of 21 |
| 6-month return | +2.9% | +8.3% | 6th lowest of 21 |
| Distance from 52-week high | -1.9% | -6.8% | 2nd highest of 21 |
| Revenue growth (TTM) | +8.3% | +14.6% | 4th lowest of 20 |
| Operating margin | 30.2% | 20.6% | 4th highest of 20 |
| Forward P/E | 16.6× | 31.9× | 3rd cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 1.1% | 23.7% | 8th least demanding of 16 |
| Growth delivered (Del g) | +12.6% | +12.1% | 7th highest of 16 |
| Hurdle (Req g minus delivered) | -11.4 pp | -11.0 pp | 8th least demanding of 16 |
| ROIC minus cost of capital | +8.0 pp | +3.3 pp | 7th highest of 19 |
| EV / EBITDA | 12.0× | 18.2× | 5th cheapest of 14 |
| Net debt / EBITDA | 1.6× | 0.6× | most indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Recordati REC.MI | Italy | $12.0B | +3% | +8% | 30% | 16.6× | 1.1% | +12.6% |
| Sbp 1177.HK | Hong Kong | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% | +5.4% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $11.6B | -4% | -19% | 19% | 40.7× | 24.9% | +6.8% |
| Mankind Pharma MANKIND.NS | India | $11.6B | +5% | +13% | 21% | 44.4× | 28.6% | +18.1% |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.5B | +5% | -4% | 9% | 32.0× | 30.7% | +12.1% |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.8B | +18% | +24% | 17% | 30.0× | n/a | n/a |
| Repligen RGEN | United States | $11.0B | +55% | +14% | 9% | 71.0× | 56.9% | +15.0% |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.0B | -1% | +44% | -38% | 1,176.1× | 55.3% | +33.6% |
| Laurus Labs LAURUSLABS.NS | India | $13.4B | +73% | +23% | 24% | 76.4× | 51.2% | +7.3% |
| TG Therapeutics TGTX | United States | $9.99B | +66% | +69% | 21% | 25.2× | 43.0% | +426.7% |
| Pharmaron Beijing 300759.SZ | China | $9.90B | +52% | +18% | 14% | 36.8× | n/a | n/a |
| Ipsen IPN.PA | France | $14.8B | +1% | +14% | 30% | 10.8× | -6.7% | +7.2% |
| Spyre Therapeutics SYRE | United States | $9.64B | +41% | n/a | n/a | n/a | n/a | n/a |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $14.9B | -7% | +14% | -43% | n/a | n/a | n/a |
| Yunnan Baiyao 000538.SZ | China | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% | +4.7% |
| PharmaEssentia 6446.TW | Taiwan | $15.0B | +67% | +78% | 40% | 31.9× | 23.7% | +94.8% |
| Madrigal Pharmaceuticals MDGL | United States | $9.25B | -22% | +93% | -11% | 81.5× | n/a | n/a |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $9.16B | +69% | +9% | 26% | n/a | -6.6% | +6.6% |
| Orion ORNAV.HE | Finland | $15.7B | +41% | +34% | 38% | 23.6× | -6.2% | +11.7% |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% | +12.5% |
| Swedish Orphan Biovitrum SOBI.ST | Sweden | $16.1B | +6% | +15% | 30% | 24.1× | -2.1% | +13.1% |